• Cryosite reported a 22% increase in revenue and a 28% increase in EBITDA for the ten months to 30 April 2026
• Record EBITDA month in April 2026
• Expansion in NPAT margin despite additional interest costs

Cryosite Limited (ASX: CTE) reported a strong financial performance for the ten months to 30 April 2026, with revenue increasing by 22% and EBITDA by 28% compared to the prior corresponding period. The company recognized a record EBITDA month in April 2026, reflecting increasing operating leverage across the business and continued growth across all revenue streams. Cryosite's performance was driven by increasing infrastructure utilization, growing demand across its Ultra-Frozen (-80°C) & Cryogenic (-196°C) segment, and expanding global clinical trial activity. The company also completed the expansion of its primary 2°C to 8°C cool room at Ferndell Street, under budget and on time, and the commissioning program for the Adderley Street freehold warehouse remains on track. Cryosite refinanced its debt facility with the National Australia Bank (NAB) on competitive terms, extending the facility maturity to 2030 and reflecting the NAB's continued confidence in Cryosite's financial position and growth strategy.

Revenue and EBITDA growth of 22% and 28% respectively for the ten months to 30 April 2026

Cryosite remains well positioned to capture long-term growth opportunities across the global life sciences sector.